Dean Y. Li - 07 Dec 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
07 Dec 2021
Transactions value $
$-325,630
Form type
4
Filing time
09 Dec 2021, 20:21:30 UTC
Previous filing
09 Dec 2021
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $-304,572 -14,900 -1.12% $20.44 1,316,000 07 Dec 2021 By Dean Y. Li 2021 GRAT F1, F2
transaction RXRX Class A Common Stock Sale $-21,058 -1,000 -0.08% $21.06 1,315,000 07 Dec 2021 By Dean Y. Li 2021 GRAT F1, F3
holding RXRX Class A Common Stock 1,422,048 07 Dec 2021 By Dean Li and Ruth Li Revocable Trust
holding RXRX Class A Common Stock 450,000 07 Dec 2021 By Dean Y. Li 2021 Family Trust
holding RXRX Class A Common Stock 597,263 07 Dec 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.995 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.03 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.